Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, and Incepta Vaccine Ltd., among others are the key players in the global meningococcal vaccines market.
The global meningococcal vaccines market stood at a volume of 172 million doses as of 2020. The global meningococcal vaccines market is expected to grow at a healthy pace in the forecast period of 2022-2027.
Neisseria meningitidis is the bacteria that causes meningococcal disease. It inflames the membrane that covers the brain and spinal cord. The market growth of meningococcal vaccines is being driven by the rising prevalence of such bacteria that trigger meningococcal meningitis. The spread of awareness about meningitis through the various clinical programmes is aiding the market growth.
The increased prevalence of numerous types of bacteria that cause meningococcal meningitis is driving the market expansion of meningococcal vaccinations. A, B, C, W, Y, and type X, which have just been traced in Africa, are the most frequent. As the demand for effective meningococcal vaccinations rises over the forecast period, this is assisting the market expansion of meningococcal vaccines. The highly unpredictable spread of this bacteria, along with the fluctuating occurrences of the disease over time across different age groups and geographies, has resulted in a significant increase in the number of clinical trials for the development of effective meningococcal vaccines around the world.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
|Headquarters:||New York, United States|
Pfizer is a leading research-based biopharmaceutical company. It is one of the biggest brands in the vaccine industry. Its product TRUMENBA is a meningococcal group B vaccine. It is approved for use in individuals in the age group of 10 to 25 years. Pfizer has over 78,000 employees researching and distributing medicines and vaccines across the world.
Sanofi is a global life sciences company committed to improving access to healthcare. Sanofi’s Menactra vaccine is a meningococcal conjugate vaccine aimed at children in the age group of 2 to 10 years. The vaccine received FDA licensure in 2005. At the time, no other vaccine was available for protection against meningococcal group B. Sanofi has over 1,10,000 employees who work to make a difference in patients’ life.
|Headquarters:||Brentford, United Kingdom|
GlaxoSmithKline is a science-led global healthcare company. The main purpose of this company is to improve the quality of human life by helping people live longer. Menveo is the meningococcal vaccine provided by GlaxoSmithKline. It prevents against the meningococcal groups A, C, Y and W-135. It is approved for people aged 2 months to 55 years. The company has over 94,000 people working for the betterment of mankind.
Incepta is the first human vaccine manufacturing company in Bangladesh. The manufacturing unit is situated at Zirabo, Savar. The company provides Ingovax, which is administered to prevent meningococcal groups A, C, Y, and W-135. The vaccine can be provided to people over the age of 2 years.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.